Answers are grounded in this paper and cite their sources.
The review analyses 47 publications that follow the pathway of clofazimine from its discovery to recognition as a Group B drug for treatment of multiple drug resistant tuberculosis. It describes its mechanism of action and effects on Mycobacterium tuberculosis, pharmacokinetics, and safety parameters.
No takes yet. Share an insight, caveat, or question.
Можокина et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: